Nektar Therapeutics (FRA:ITH0) Cyclically Adjusted Book per Share: €47.56 (As of Mar. 2026)


FRA:ITH0 Nektar Therapeutics FRA:ITH0
47 GF Score
Price €61.10
GF Value €5.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Cyclically Adjusted Book per Share?

Nektar Therapeutics FRA:ITH0 +10.97% 47 Cyclically Adjusted Book per Share is €47.56 as of Mar. 2026. GuruFocus rates FRA:ITH0 with a GF Score™ of 47/100 and a GF Value™ of €5.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nektar Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €16.912. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €47.56 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Nektar Therapeutics's average Cyclically Adjusted Book Growth Rate was 3.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nektar Therapeutics was 49.10% per year. The lowest was -26.40% per year. And the median was 1.30% per year.

As of today (2026-07-01), Nektar Therapeutics's current stock price is €61.10. Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €47.56. Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is 1.28.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 5.98.


Nektar Therapeutics  (FRA:ITH0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=61.10/47.56
=1.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 5.98.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nektar Therapeutics Cyclically Adjusted Book per Share Related Terms


Nektar Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Cyclically Adjusted Book per Share Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.68 47.66 49.10 56.01 49.80

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.79 49.45 51.68 49.80 47.56

FRA:ITH0 vs OCUL, PVLA, GENB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:ITH0
47GF Score
Nektar Therapeutics FRA:ITH0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.912/330.2130*330.2130
=16.912

Current CPI (Mar. 2026) = 330.2130.

Nektar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -3.836 241.018 -5.256
201609 -6.581 241.428 -9.001
201612 8.179 241.432 11.187
201703 4.056 243.801 5.494
201706 0.290 244.955 0.391
201709 6.748 246.819 9.028
201712 6.978 246.524 9.347
201803 4.367 249.554 5.778
201806 138.552 251.989 181.562
201809 132.975 252.439 173.943
201812 130.499 251.233 171.524
201903 124.465 254.202 161.682
201906 118.148 256.143 152.313
201909 115.347 256.759 148.346
201912 107.491 256.974 138.127
202003 98.943 258.115 126.580
202006 93.578 257.797 119.864
202009 83.124 260.280 105.458
202012 73.758 260.474 93.506
202103 68.739 264.877 85.695
202106 61.307 271.696 74.511
202109 55.373 274.310 66.658
202112 48.634 278.802 57.602
202203 44.449 287.504 51.052
202206 34.733 296.311 38.707
202209 33.228 296.808 36.968
202212 27.532 296.797 30.632
202303 17.832 301.836 19.508
202306 14.343 305.109 15.523
202309 11.741 307.789 12.596
202312 9.414 306.746 10.134
202403 9.522 312.332 10.067
202406 6.033 314.175 6.341
202409 3.582 315.301 3.751
202412 4.683 315.605 4.900
202503 1.024 319.799 1.057
202506 -1.685 322.561 -1.725
202509 3.689 324.800 3.750
202512 3.765 324.054 3.837
202603 16.912 330.213 16.912

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €47.56 mean?
Nektar Therapeutics (FRA:ITH0) has a Cyclically Adjusted Book per Share of €47.56 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Cyclically Adjusted Book per Share too high?
Nektar Therapeutics' current Cyclically Adjusted Book per Share is €47.56. Overall, Nektar Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Cyclically Adjusted Book per Share compare to OCUL and PVLA?
Nektar Therapeutics' Cyclically Adjusted Book per Share of €47.56 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Cyclically Adjusted Book per Share is €47.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.05, compared to a current price of €61.10 — trading 1109.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is €47.56. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current Cyclically Adjusted Book per Share is €47.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €61.10 is trading 1109.9% above its estimated GF Value™ of €5.05. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:ITH0:

  • Cyclically Adjusted Book per Share: €47.56
  • GF Value™: €5.05 vs. price of €61.10 (1109.9% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for FRA:ITH0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€61.10
Price
€5.05
GF Value